Angiotensin Converting Enzyme Inhibitors. (Record no. 59572)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06858nam a22004573i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC3018321 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729124057.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2009 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781607410959 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781606926192 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC3018321 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL3018321 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr10660182 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)923658145 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | QP572.A54 -- A543 2009eb |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 572/.744 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | DeBrue, Anne N. |
| 245 10 - TITLE STATEMENT | |
| Title | Angiotensin Converting Enzyme Inhibitors. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | New York : |
| Name of producer, publisher, distributor, manufacturer | Nova Science Publishers, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2009. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2009. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (252 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- ANGIOTENSIN CONVERTING ENZYME INHIBITORS -- Contents -- Preface -- Angiotensin Converting Enzyme Inhibitors -- Abstract -- Introduction - The Components of the Renin Angiotensin Aldosterone System (RAAS) -- Structure and Structure Activity Relationships of the ACEIs -- Clinical Indications and Uses of the ACEIs -- Adverse Effects of the ACE Inhibitors with Special Reference to Worsening Renal Failure in CKD Patients -- Conclusion/Post-Script -- References -- Adverse Effects of Angiotensin-Converting Enzyme Inhibitor: A Review of the Literature -- Abstract -- Introduction -- ACEI-Associated Cough -- Hypersensitivity Reaction During Hemodialysis -- ACEI-Associated Anemia -- ACEI-Induced Lung Disease -- References -- Plant-Derived Substances as ACE Inhibitors - Biosynthesis-Activity Relationship of Flavonoids, Terpenes and Sterols on Angiotensin-Converting Enzyme Activity in Human Endothelial Cells -- Abstract -- Introduction -- Aim of this Study -- Material and Methods -- Results (Table 1) -- Conclusion -- Acknowledgments -- References -- The Proper Use of Angiotensin-Converting Enzyme Inhibitors in Patients with Chronic Kidney Disease -- Abstract -- Introduction -- Effects of ACE inhibitors on Renal and Glomerular Hemodynamics -- Effects of ACE Inhibitors on Proteinuria -- Increasing the Doses of ACE Inhibitors or the Addition of ARB? -- Excretion and Plasma Concentration of ACE Inhibitors in Patients with Chronic Renal Failure -- Upper Limit of Serum Creatinine to Add on ACE Inhibitor -- Long-Term Renoprotective Effects and Escape Phenomenon by Use of ACE Inhibitors -- Side Effects of ACE Inhibitors in Patients with Chronic Renal Failure -- Influence of Gene Polymorphisms on Renoprotective Effects of ACE Inhibitors -- Compliance of Taking ACE Inhibitors -- Additional Therapy with ACE Inhibitors. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Clinical Approach for Proper Use of ACE Inhibitors -- Summary -- Patients and Methods -- Acknowledgements -- References -- Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic Function -- Abstract -- Abbreviation: -- * Median follow-up -- Potential Mechanisms of ACEI Beneficial Activity in Patients with CAD -- Clinical Uses of ACEI in Cardiovascular Diseases -- Randomized Clinical Trials Examining the Use of ACEI in Patients with CAD and Preserved LV Systolic Function -- Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme (IMAGINE) Trial -- Meta Analysis of the Effects of ACEI in Patients with Normal LV Function and CAD -- Putting it Together -- References -- Dual Blockade of the Renin-Angiotensin System: Angiotensin Converting Enzyme Inhibition, Angiotensin Receptor Blockade and Renin Inhibition -- Abstract -- Introduction -- Differences in the Mechanisms of Action of RAS Blockers -- Rationale of Dual RAS Blockade -- Dual RAS Blockade and Blood Pressure -- Dual RAS Blockade and Target Organ Damage -- Dual RAS Blockade and Cardiovascular-Renal Outcome -- Safety of Long-Term Dual RAS Blockade -- Conclusion -- References -- Angiotensin-Converting Enzyme Inhibitors in Patients with Bilateral Atherosclerotic Renal Artery Stenosis -- Abstract -- Introduction -- Definition -- Pathophysiology -- Clinical Manifestations -- Diagnosis -- Therapeutic Approach -- Cardiovascular Risk Associated with Aras -- Angiotensin Inhibitors in Animal Studies of ARAS -- Angiotensin Inhibitors in Human Studies of ARAS -- Acute Renal Failure and ACE Inhibitors -- Heterogeneity of Patient Subtypes -- Future Perspectives -- Conclusion -- References -- Angiotensin Converting Enzyme Inhibitors in Renal Disease -- Introduction. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | The Experimental Basis of Ace Inhibitors Nephroprotection -- Renin-Angiotensin System Actions Inside the Kidney -- Proposed Mechanisms for Renoprotection -- Clinical Use of Ace Inhibitors in Renal Disease -- Beyond Blood Pressure Control? -- Meta-Analyses on Renoprotective Effects of Ace Inhibitors -- Combination of Ace Inhibitors and ARBS in Renal Disease -- Ace Inhibitors or ARBS for Renal Disease?. -- Safe Use in Patients with Renal Failure -- References -- The Kallikrein- Kinin Pathways in Mediating the Hypotensive Action of Angiotensin Converting Enzyme (ACE) Inhibitors -- Abstract -- Introduction -- Kallikrein-Kinin System -- Kinin Receptors -- Kallikrein-Kinin and Renin Angiotensin Systems Interaction -- Kallikrein-Kinin System During Hypertension -- Antihypertensive Effects of Kininase II Inhibitors (ACEIs) -- Kinin Receptors Antagonists and Angiotensin Converting Enzyme (Kininase Ii) Inhibitors -- Summary -- References -- Angiotension Converting Enzyme Inhibitors: Improving Utilization and Adherence -- Abstract -- Introduction -- Magnitude of the Problem -- Barriers to Use -- Improving Adherence: Solutions -- Conclusion -- References -- Angiotensin Blockade in Pediatric Chronic Kidney Disease -- Abstract -- Introduction -- Renoprotection from Angiotensin Blockade -- Pediatric Studies on Angiotensin Blockade -- Effect On Proteinuria -- Effect on BP -- Progression of CKD -- Safety Considerations -- Conclusion -- References -- Index. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Angiotensin converting enzyme -- Inhibitors. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Kidneys -- Diseases -- Chemotherapy. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | DeBrue, Anne N. |
| Title | Angiotensin Converting Enzyme Inhibitors |
| Place, publisher, and date of publication | New York : Nova Science Publishers, Incorporated,c2009 |
| International Standard Book Number | 9781606926192 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3018321">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3018321</a> |
| Public note | Click to View |
No items available.